Back

Amgen

12/01/2023

AMGN is a slow growth company; 2023 sales should increase by just about 5%. Yet, expectations for the biotech’s landmark lung cancer drug, Lumakras, are high, i.e., it should become a new blockbuster. For now, the company has to provide new research data to the FDA which will delay this year’s GTM for the product.

Back

Related articles

Walt Disney Co

12/01/2023

With Disney’s shares down about 50% from their 2021 high, the market is focused on content costs, increasing direct-to-consumer competition and theme park recession risks—concerns that may linger into the...

Read More >>>

TSMC – Taiwan Semiconductor Manufacturing Co

12/01/2023

The world’s largest semiconductor foundry is facing multiple issues ranging from geopolitical and macro to economic concerns. While the market for foundry products is weak, we see some good opportunities...

Read More >>>

Universal Display Corp

12/01/2023

On the back of new and extended usages, the commercialization of the lighting company’s innovative blue-emitter technology for smartphones and OLED TVs should accelerate in 2023. In a given addressable...

Read More >>>

Vestas Wind Systems A/S

12/01/2023

Over the next three years, the supplier of wind turbines should see 7% average annual growth in gigawatts of capacity to be delivered. Given the geopolitical situation and elevated prices...

Read More >>>

Repsol SA

12/01/2023

The company is active in the down and upstream business, but its strength is in the refining and distribution of natural gas. About two-thirds of its upstream production is oriented...

Read More >>>